6-acetyl-7-amino-5-phenylfurazano[3,4-b]pyridine | 339589-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-acetyl-7-amino-5-phenylfurazano[3,4-b]pyridine
• 英文别名: 1-(7-Amino-5-phenyl[1,2,5]oxadiazolo[3,4-b]pyridin-6-yl)ethanone；1-(7-amino-5-phenyl-[1,2,5]oxadiazolo[3,4-b]pyridin-6-yl)ethanone
• CAS: 339589-58-1
• 化学式: C₁₃H₁₀N₄O₂
• mdl: MFCD00825520
• 分子量: 254.248
• InChiKey: WCVHYOVMLHUVCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  94.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 6-acetyl-7-amino-5-phenylfurazano[3,4-b]pyridine 以 苯 为溶剂， 反应 1.0h， 以97%的产率得到6-acetyl-7-(dimethylaminomethylenamino)-5-phenylfurazan[3,4-b]pyridine
  参考文献：
  名称：

  呋喃并[3,4- b ] [1,6]萘啶的首次合成

  摘要：

  使6-乙酰基-7-氨基呋喃并[3,4- b ]吡啶与DMFDMA反应，得到N，N-二甲基甲am ，通过用甲醇钠处理，将其环化成新颖的呋喃山稠合的[1,6]萘啶体系。三环体系的特征在于X射线晶体学。

  DOI：

  10.1002/jhet.5570440415
• 作为产物：
  描述：

  4-amino-4-(4-aminofurazan-3-yl)-3-benzoylbut-3(E)-en-2-one 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 5.0h， 以82%的产率得到6-acetyl-7-amino-5-phenylfurazano[3,4-b]pyridine
  参考文献：
  名称：

  摘要：

  In the presence of nickel acetylacetonate, beta-dicarbonyl compounds readily add at the nitrile group of 4-R-3-cyanofurazans to form enaminofurazans. The adducts obtained from 4-amino-3-cyanofurazan underwent intramolecular cyclization on heating with AcOH in EtOH to give furazano[3,4-b]pyridine derivatives in high yields.

  DOI：

  10.1023/a:1014075327382

文献信息

• Non-Peptidic Inhibitors of AKAP/PKA Interaction
  申请人：Klussmann Enno

  公开号：US20090176773A1

  公开（公告）日：2009-07-09

  The invention relates to non-peptidic molecules which modulate, especially inhibit, the interaction of protein kinase A (PKA) and A kinase anchor proteins (AKAP) and to a host or target organism that comprises said non-peptidic compounds or recognition molecules directed to said compounds, such as e.g. antibodies or chelating agents. The invention also relates to a pharmaceutical agent, especially for use in the treatment of diseases that are associated with a disturbance of the cAMP signal path, especially insipid diabetes, hypertonia, pancreatic diabetes, duodenal ulcer, asthma, heart failure, obesity, AIDS, edema, hepatic cirrhosis, schizophrenia and others. The invention also relates to the use of the inventive molecules.
• ——
  作者：L. S. Vasil"ev、A. B. Sheremetev、N. K. Khoa、Z. K. Dem"yanets、D. E. Dmitriev、V. A. Dorokhov

  DOI：10.1023/a:1014075327382

  日期：——

  In the presence of nickel acetylacetonate, beta-dicarbonyl compounds readily add at the nitrile group of 4-R-3-cyanofurazans to form enaminofurazans. The adducts obtained from 4-amino-3-cyanofurazan underwent intramolecular cyclization on heating with AcOH in EtOH to give furazano[3,4-b]pyridine derivatives in high yields.
• The first synthesis of furazano[3,4-<i>b</i>][1,6]naphthyridines
  作者：Leonid S. Vasilev、Aleksei B. Sheremetev、Vladimir A. Dorokhov、Kyrill Yu. Suponitsky

  DOI：10.1002/jhet.5570440415

  日期：2007.7

  Reaction of 6-acetyl-7-aminofurazano[3,4-b]pyridines with DMFDMA afforded N,N-dimethylformamidines that were cyclized to the novel furazan-fused [1,6]naphthyridine system by treatment with sodium methylate in good yield. The tricyclic system is characterized by X-ray crystallography.

  使6-乙酰基-7-氨基呋喃并[3,4- b ]吡啶与DMFDMA反应，得到N，N-二甲基甲am ，通过用甲醇钠处理，将其环化成新颖的呋喃山稠合的[1,6]萘啶体系。三环体系的特征在于X射线晶体学。

表征谱图